Risk factors for the development of a first episode of Pneumocystis carinii pneumonia (PCP) were investigated in the Adult and Adolescent Spectrum of Disease Project, a medical record review study involving longitudinal follow-up of human immunodeficiency virus-infected adults in 9 US cities. Risk factors included decreasing CD4 lymphocyte count and history of AIDS-defining illness, non-P. carinii pneumonia, oral thrush, or unexplained fever for §2 days; PCP prophylaxis was protective. PCP incidence/100 person-years of observation among persons not prescribed PCP prophylaxis was higher in those with CD4 lymphocyte counts õ250 cells/mL or CD4 cell percent õ14% (8.3; 95% confidence interval [CI], 7.7-9.0) than in persons with CD4 cell counts õ200 or history of thrush or fever, which constitute current criteria for prophylaxis against PCP (5.9; 95% CI, 5.5-6.4). Because of increased efficiency in capturing persons at highest risk, CD4 cell count õ250 or CD4 cell percent õ14% should be considered as criteria for prophylaxis against first episodes of PCP. HIV-infected persons §13 years of age in ú90 medical care
Since the initial descriptions of Pneumocystis carinii pneucases per 100 person-years of follow time (incidence density [ID]) in persons who had various combinations of PCP risk monia (PCP) in patients with AIDS in 1981 [1] , PCP has remained the most common serious opportunistic infection in factors but who had not been offered PCP prophylaxis. adults and adolescents infected with human immunodeficiency virus (HIV) in the United States [2] . Chemoprophylaxis against PCP has been recommended since 1989 [3] and is currently Methods recommended for HIV-infected adolescents and adults with CD4 lymphocyte counts õ200 cells/mL, history of oral candidi-ASD project. The methods of the ASD Project have been deasis, history of unexplained fever for §2 weeks, or history of scribed previously [5] . Briefly, beginning in 1990, HIV-infected PCP [4] . The drug of choice is trimethoprim-sulfamethoxazole; persons §13 years of age were enrolled in 116 medical facilities in 11 US cities. Because of incomplete information on opportunistic dapsone and aerosolized pentamidine are alternatives for those illnesses from 2 cities, data from 108 facilities in 9 cities are who cannot tolerate trimethoprim-sulfamethoxazole. However, included in this analysis (Atlanta, New Orleans, Dallas, San Antosome cases of PCP occur in persons in medical care who have nio, Houston, Detroit, Denver, Los Angeles, and Seattle). When not been offered PCP prophylaxis because they lack any of the patients are enrolled, medical records are reviewed for demothese risk factors. HIV-infected persons §13 years of age in ú90 medical care
Laboratory tests include CD4 lymphocyte counts. Medical records facilities in 9 cities in the United States [5] . To determine are reviewed every 6 months thereafter until the patient's death or loss to follow-up. These analyses were done on data obtained at whether the current criteria for PCP prophylaxis could be imthe Centers for Disease Control and Prevention (CDC) through proved, we then computed and compared the number of PCP February 1997 , at which time nearly 35,000 persons had been enrolled in the 9 cities.
Definitions of persons ''in care,'' PCP prophylaxis, and diagnosis of PCP. Because subjects may be diagnosed with an AIDS- defining illness, non -P. carinii pneumonia, and unexplained [6] . Both confirmed and presumptive cases were included in the fever were 1.8 -2.0 among persons with CD4 cell counts §200.
analyses; differences in risk factors associated with both combined PCP prophylaxis was protective ( between history of AIDS illnesses and PCP. A similar assessAssumptions of proportional hazards were investigated by using ment of the association between history of non -P. carinii pneuplots of weighted Schoenfeld residuals versus time [8] . Relationships between antecedent diagnosis of AIDS opportunistic infecmonia and PCP could not be made, because there were too tion, non-P. carinii pneumonia, oral candidiasis, and unexplained few persons with a history of non -P. carinii pneumonia for fever and different levels of CD4 lymphocyte counts as risk factors which the cause was specified. table 2 ). Among persons with CD4 cell counts õ250 or CD4 cell percent õ14%, the ID was (577/6936) 1 100 Å 8.3 (95% CI, 7.7 -9.0); among those with any of these risks or history Results of AIDS illness or non -P. carinii pneumonia, the ID was (635/ Risk factors for PCP. As of February 1997, 24 ,189 persons 8927) 1 100 Å 7.1 (95% CI, 6.6 -7.6). History of oral thrush, without a history of PCP had been enrolled in ASD and had history of unexplained fever, CD4 cell count õ300, and CD4 §1 month of follow-up; 22,698 of these had §1 month of cell percent õ18% were consistently associated with lower IDs follow-up after a CD4 cell count was available and were inin these analyses (table 2) . cluded in the analysis. The 1491 excluded on the basis of Because the current criteria for prophylaxis against the first episode of PCP include CD4 cell count õ200 or history of insufficient CD4 cell data were nearly twice as likely to be / 9d52$$oc10 08-24-98 13:18:25 jinfa UC: J Infect NOTE. Analysis includes all subjects without prior history of PCP who were ''in care.'' Both confirmed and presumptive cases of PCP are included. Percentages in analyses that include CD4 (which refers to CD4 cell count) may not sum to 100. CD4 cell count is time-varying covariate; as such, no. represents persons who at some observation time were within that CD4 cell range. In CD4 cell count -stratified analysis of persons with antecedent illness, no. represents persons who had antecedent illness and were observed in that CD4 cell range; % is proportion of all persons observed in that CD4 cell range.
* Compared with persons 10 years younger at enrollment.
oral candidiasis or unexplained fever, we also determined the P. carinii pneumonia (638 cases vs. 635 cases) but with an ID of 5.9 (vs. 7.1; 95% CI, 5.5 -6.4 and 6.6 -7.6, respectively); ID of PCP in persons who had one or more of these risk factors but who had not been prescribed PCP prophylaxis. This that is, persons in this category were at lower risk for PCP (table 3) . combination of risk factors (i.e., criteria in current guidelines) was associated with a number of PCP cases similar to that Since our analyses included cases of PCP diagnosed both definitively and presumptively, and since 1350 of the 2625 associated with the combination of CD4 cell count õ250, CD4 cell percent õ14%, history of AIDS illness, or history of noncases (51.4%) were diagnosed presumptively, we repeated our / 9d52$$oc10 08-24-98 13:18:25 jinfa UC: J Infect NOTE. Hx Å history. PCP cases include both confirmed and presumptive cases. Patients' observation time is computed from most recent CD4 (which refers to CD4 cell count) or diagnosis of risk factor. Data are ordered within groups by incidence density; risk factor with highest incidence density is listed first.
/ 9d52$$oc10
08-24-98 13:18:25 jinfa UC: J Infect phylaxis in relation to current guideline for prophylaxis.
In our analysis, low CD4 cell count was the strongest risk factor for a first episode of PCP, a finding that is consistent by residual pulmonary pathology that in some unknown way NOTE. Hx Å history. PCP cases include both confirmed and presumptive increases the risk that an infection with P. carinii will become cases. Patients' observation time is computed from most recent CD4 (which established (or predisposing pathology that increases the risk refers to CD4 cell count) or diagnosis of risk factor.
both for non -P. carinii pneumonia and PCP). Some of these * Cases diagnosed after CD4 cell count õ200 cells/mL or diagnosis of oral thrush or unexplained fever.
cases of non -P. carinii pneumonia might have been undiagnosed PCP.
Our analysis of cases of PCP per 100 person-years of observation (ID) during periods without prescribed PCP prophylaxis analyses with attention to the definitively diagnosed (conindicated that for total and confirmed cases only, persons with firmed) cases only. In the risk factor analysis, presumptive a CD4 cell count õ250 or a CD4 cell percent õ14% had the cases were more likely than confirmed cases to be diagnosed highest IDs for the development of PCP; the ID in this group at higher CD4 cell levels and to be diagnosed in blacks or in exceeded those for other groups examined, including persons those with heterosexual or unknown HIV risk; the beneficial with a history of oral candidiasis or unexplained fever, which association with prophylaxis was stronger for confirmed than are recommended criteria for prophylaxis in current guidelines. for presumptive cases, but the association with unexplained
In fact, in the overall analysis, among persons with CD4 cell fever was weaker (data not shown). In the ID analysis, the IDs counts §250 and CD4 cell percent §14%, none of the IDs for confirmed cases were roughly one-half of those shown in for PCP exceeded that in the overall population (3.2%; 95% tables 2 and 3 (because of the exclusion of presumptive cases).
CI, 2.9 -3.4); indeed, none exceeded 3.0%. These observations The ordering of the PCP risks was identical to that shown for suggest that this combination of risk factors may constitute the the combined analysis with regard to CD4 cell count õ200, best criteria for prophylaxis against the first episode of PCP. CD4 cell percent õ14%, and CD4 cell count õ250, but subOur analysis also indicated that the combination of CD4 cell jects with CD4 cell counts õ300 and CD4 cell percent õ18% count õ250, CD4 cell percent õ14%, history of AIDS illness, had higher IDs than did subjects with history of AIDS illness or history of non -P. carinii pneumonia preceded 635 of the or history of non -P. carinii pneumonia (data not shown).
PCP cases in the analysis, a number similar to that associated with the criteria in the current guidelines (638), but with a higher ID (7.1 vs. 5.9). Therefore, this combination could also Discussion be considered for prophylaxis, although in the analysis of confirmed cases only, histories of AIDS illness and non -P. carinii Current indications for chemoprophylaxis against the first episode of PCP in HIV-infected adults and adolescents include pneumonia were not associated with the same conclusion.
One difficulty in interpreting our data is the possibility that CD4 cell count õ200 or history of oral candidiasis or unexplained fever of §2 weeks' duration [4] . Although low CD4
persons not prescribed PCP prophylaxis may be followed up less frequently, thus having less frequent CD4 cell counts, and cell count is a well-documented risk factor for PCP, the additional indications for PCP prophylaxis emanate from only two a greater likelihood that PCP will develop after a CD4 cell count §200 is observed. In our ID analysis, the median interval studies, to our knowledge [9, 10] . Providers continue to debate whether prophylaxis should be offered to other patients, such between measurement of CD4 cell count and PCP diagnosis was 6 months (25% quartile, 2 months; 75% quartile, 14 as those with CD4 cell counts ú200 but õ250 or CD4 cell percent õ14% [11] . Therefore, it seemed reasonable to reassess months). Therefore, it is possible that more timely measurement / 9d52$$oc10 08-24-98 13:18:25 jinfa UC: J Infect of CD4 cells would have decreased the risks we observed in we repeated our analyses limiting PCP cases to the 1275 (of 2625) that were diagnosed definitively and found no significant persons with CD4 cell counts §200.
The rate of decline of the CD4 cell count could conceivably changes in our results, with the exception of the ordering of the IDs for history of AIDS illness and history of non -P. contribute to assessment of risk in persons with CD4 cell counts §200. We found that a decline of §15 CD4 cells/month was carinii pneumonia. Despite these limitations, ASD offers the opportunity to examine a large database that is diverse with an independent risk factor for PCP when this variable was entered into our multivariate analysis (risk ratio, 1.21; 95% CI, regard to age, sex, race, HIV exposure mode, and geography; such a database cannot be found elsewhere in the United States. 1.07 -1.36). However, the number of subjects with CD4 cell count §200 but õ250 who developed PCP and who had such
In conclusion, our data suggest that (1) a CD4 cell count õ250 or CD4 cell percent õ14% or (2) any one or more of data available was too small to generate meaningful information regarding this variable in the ID analysis (data not shown).
CD4 cell count õ250, CD4 cell percent õ14%, history of AIDS illness, or history of non -P. carinii pneumonia should Measurement of HIV plasma RNA (virus load) may also prove useful in predicting risk of PCP; elevated levels of HIV be considered as the criteria for prophylaxis against the first episode of PCP. However, because of the limitations of this RNA have been shown to constitute a risk of PCP and other opportunistic infections independent of CD4 cell count [14] . study, such a policy change should await confirmation of our findings in other populations, as well as thorough cost-effecHowever, collection of HIV RNA data has been instituted only recently in the ASD project and could not be assessed in this tiveness research to determine the threshold ID at which PCP prophylaxis should be offered. analysis.
Another issue in interpreting our data is determining the Finally, there are many reasons that HIV-infected persons in the United States continue to develop PCP. As many as oneoptimal ID threshold at which PCP prophylaxis should be offered. Providers would be unwilling to offer prophylaxis to half of all cases of PCP occur in persons who are unaware of their HIV infection or have not otherwise received medical all HIV-infected persons (a strategy that would prevent the maximum number of cases of PCP) because of the risk of drug care [18 -20] . Others occur because of the provider's failure to offer prophylaxis or poor patient adherence to prophylaxis. toxicity. Trimethoprim-sulfamethoxazole, the drug of choice for PCP prophylaxis, causes significant toxicity in up to 40% Therefore, in addition to the appropriate use of PCP chemoprophylaxis, the prevention of this disease will require counseling of HIV-infected patients [15] , although recent data suggest that a gradual introduction of trimethoprim-sulfamethoxazole, and testing for HIV infection, referral to medical care, and education of both patients and providers. compared with introduction at the full dose of one doublestrength tablet per day, may improve tolerance to the drug [16] . In addition to the risk of PCP, a true assessment of the
